Buparlisib

Small molecule

Also known as BKM120

Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2025-06-02), after a negative readout

Adlai Nortye's Phase 3 BURAN (NCT04338399) did not improve overall survival over paclitaxel alone in recurrent or metastatic HNSCC, and the company stopped the buparlisib programme. Novartis, the originator, had licensed global rights to Adlai Nortye in 2018. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Other / comorbidity
NCT01633060 · Novartis Pharmaceuticals
2012-10-03 – 2017-09-21 · Metastatic Breast Cancer
What this study did
Phase 2/3 (1)
Other / comorbidity
Phase 2 (32)
Other / comorbidity
NCT02159066 · Pfizer
2014-07-23 – 2023-01-10 · Melanoma
What this study did
NCT02220855 · Patrick Joseph Loehrer Sr.
2014-10-01 – 2021-03-09 · Thymoma
What this study did
NCT01551030 · Memorial Sloan Kettering Cancer Center
2012-03 – 2020-09-02 · Metastatic Transitional Cell Carcinoma of the Urothelium
What this study did
NCT02340780 · Canadian Cancer Trials Group
2015-04-27 – 2020-04-28 · Chronic Lymphocytic Leukemia
What this study did
NCT02000882 · US Oncology Research
2014-05-29 – 2019-03-29 · Brain Metastases, Breast Cancer, Metastatic Breast Cancer
What this study did
NCT01737450 · Centre Leon Berard
2013-01 – 2019-03 · Head and Neck Neoplasms, Neoplasm Metastasis, Recurrent Disease, Progressive Disease
What this study did
NCT01339052 · L. Nicolas Gonzalez Castro, MD, PhD
2011-09 – 2019-02 · Glioblastoma
What this study did
NCT02452294 · University Hospital Tuebingen
2015-07 – 2018-07 · Malignant Melanoma, Metastases
What this study did
NCT01487265 · SCRI Development Innovations, LLC
2014-03 – 2017-12-11 · Non Small Cell Lung Cancer
What this study did
NCT02404844 · University Hospital, Essen
2014-12 – 2017-10-19 · Breast Cancer
What this study did
NCT01613677 · Novartis Pharmaceuticals
2015-11 – 2017-09 · Treatment for Metastatic or Locally Advanced Cervical Cancer
What this study did
NCT01693614 · Novartis Pharmaceuticals
2013-02-28 – 2017-07-21 · Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
What this study did
NCT01923168 · Novartis Pharmaceuticals
2014-03-11 – 2017-07-08 · Breast Cancer
What this study did
NCT02303041 · Anne Chang
2015-02 – 2017-06 · Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Neoplasms, Basal Cell Nevus Syndrome
What this study did
NCT01852292 · Novartis Pharmaceuticals
2013-10-01 – 2017-03-30 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT01830504 · Hospices Civils de Lyon
2013-04 – 2017-01 · Thyroid Cancers
What this study did
NCT02301364 · Memorial Sloan Kettering Cancer Center
2014-11-20 – 2016-10-11 · Lymphoma, Primary Central Nervous System Lymphoma, Recurrent/Refractory Secondary Central Nervous System Lymphoma
What this study did
NCT01833169 · Novartis Pharmaceuticals
2013-03-29 – 2016-09-26 · PI3K Pathway Activated Tumors
What this study did
NCT01806649 · Prince of Songkla University
2013-07-01 – 2016-04-30 · Esophageal Cancer
What this study did
NCT01397877 · ARCAGY/ GINECO GROUP
2011-12 – 2016-03 · Endometrial Cancer
What this study did
NCT01385293 · Andrew J. Armstrong, MD
2011-08 – 2016-02 · Prostate Cancer, Metastatic (Spread to Other Areas of the Body)
What this study did
NCT01629615 · SOLTI Breast Cancer Research Group
2012-06 – 2015-10 · Breast Cancer
What this study did
NCT01790932 · Dana-Farber Cancer Institute
2012-06 – 2015-09 · Breast Cancer
What this study did
NCT01953445 · Washington University School of Medicine
2014-08 – 2015-07 · Breast Neoplasms
What this study did
NCT01816594 · Novartis Pharmaceuticals
2013-09-03 – 2015-02-18 · HER2-positive Newly Diagnosed, Primary Breast Cancer
What this study did
NCT01695473 · Won Kim
2013-04-23 – 2015-02-05 · High Risk Prostate Cancer
What this study did
NCT02035124 · SCRI Development Innovations, LLC
2014-04 – 2015-01 · Advanced Prostate Cancer
What this study did
NCT01297491 · Novartis Pharmaceuticals
2011-05 – 2014-10 · Non-small Cell Lung Cancer
What this study did
NCT01527877 · Yonsei University
2012-09 – 2014-08 · Head Neck Cancer Squamous Cell Metastatic, Head Neck Cancer Squamous Cell Recurrent
What this study did
NCT01550380 · University of Utah
2014-05 – 2014-07 · Endometrial Cancer
What this study did
NCT01289041 · Novartis Pharmaceuticals
2011-02 – 2014-03 · Advanced Endometrial Cancer
What this study did
NCT01501604 · Massachusetts General Hospital
2012-01 – 2013-08 · Lung Cancer, Breast Cancer, Colorectal Cancer, Cholangiocarcinoma, Solid Tumors
What this study did
Phase 1/2 (7)
Other / comorbidity
NCT01816984 · University of Chicago
2013-05 – 2020-09 · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
What this study did
NCT01591421 · Canadian Cancer Trials Group
2012-09-06 – 2019-11-12 · Metastatic Colorectal Cancer
What this study did
NCT01349660 · SCRI Development Innovations, LLC
2011-12 – 2018-12-29 · Glioblastoma Multiforme
What this study did
NCT01589861 · Institut Paoli-Calmettes
2011-12 – 2017-10-10 · Breast Cancer
What this study did
NCT01512251 · University of California, San Francisco
2012-06-09 – 2017-03-21 · BRAF Mutant Metastatic Melanoma
What this study did
NCT01870726 · Novartis Pharmaceuticals
2014-01-09 – 2016-12-23 · c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
What this study did
NCT01132664 · Novartis Pharmaceuticals
2010-05 – 2014-08 · Metastatic Breast Cancer, HER2+ Breast Cancer
What this study did
Phase 1 (45)
Other / comorbidity
NCT04975958 · Adlai Nortye Biopharma Co., Ltd.
2021-09-07 – 2025-01-24 · Locally Advanced Solid Tumor
What this study did
NCT02756247 · Memorial Sloan Kettering Cancer Center
2016-05-09 – 2022-10-06 · Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma
What this study did
NCT02113878 · Dana-Farber Cancer Institute
2014-09-29 – 2022-01-01 · Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma, Carcinoma of Larynx, Cancer of Nasopharynx
What this study did
NCT02614508 · Emory University
2016-01 – 2019-08 · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT02049541 · Kami Maddocks, MD
2014-07-21 – 2019-04-09 · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
What this study did
NCT02058381 · Novartis Pharmaceuticals
2014-05-06 – 2018-06-19 · Pre-menopausal Breast Cancer, PI3K Pathway Inhibition
What this study did
NCT02088684 · Novartis Pharmaceuticals
2014-05-19 – 2018-04-17 · Breast Cancer
What this study did
NCT02439489 · Fondazione Michelangelo
2012-12 – 2017-12-31 · Solid Tumors
What this study did
NCT01363232 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2011-08 – 2017-12-18 · Advanced Solid Tumors, Selected Solid Tumors
What this study did
NCT02487823 · Institut Paoli-Calmettes
2014-10 – 2017-11 · Non Castrate Metastatic Prostate Cancer
What this study did
NCT02128724 · University of Oxford
2013-04 – 2017-10-17 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01730248 · Novartis Pharmaceuticals
2012-12-18 – 2017-09-28 · Myelofibrosis
What this study did
NCT01473901 · Novartis Pharmaceuticals
2011-12-30 – 2017-05-17 · Glioblastoma
What this study did
NCT01470209 · Emory University
2012-01 – 2017-05 · Solid Tumors, Lung Cancer
What this study did
NCT01297452 · Memorial Sloan Kettering Cancer Center
2011-02-15 – 2017-03-29 · Solid Tumors
What this study did
NCT01719250 · Mayo Clinic
2012-12 – 2017-03-22 · Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
What this study did
NCT01339442 · Washington University School of Medicine
2011-11-14 – 2016-12-28 · Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT02154776 · Novartis Pharmaceuticals
2014-06-27 – 2016-10-26 · Advanced or Metastatic Breast Cancer
What this study did
NCT01396499 · M.D. Anderson Cancer Center
2012-07 – 2016-10 · Leukemia
What this study did
NCT01741753 · Dana-Farber Cancer Institute
2012-11 – 2016-09-01 · Prostate Cancer
What this study did
NCT01723800 · City of Hope Medical Center
2013-07 – 2016-09 · Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
NCT01283048 · Toni Choueiri, MD
2011-09 – 2016-09 · Renal Cell Carcinoma
What this study did
NCT01971489 · Roswell Park Cancer Institute
2015-09 – 2016-08 · Adult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT01468688 · Novartis Pharmaceuticals
2012-04-20 – 2016-07-29 · 3rd Line GIST
What this study did
NCT01934361 · Novartis Pharmaceuticals
2014-02-28 – 2016-07-07 · Recurrent Glioblastoma Multiforme
What this study did
NCT02194049 · University of California, Davis
2014-07 – 2016-06 · Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01540253 · Roswell Park Cancer Institute
2012-05 – 2016-06 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01248494 · Vanderbilt-Ingram Cancer Center
2010-11 – 2016-05 · Metastatic Breast Cancer
What this study did
NCT01571024 · UNC Lineberger Comprehensive Cancer Center
2012-05 – 2016-03 · Advanced Solid Tumors, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
What this study did
NCT01304602 · University of Kansas Medical Center
2011-02 – 2015-10 · Colorectal Cancer
What this study did
NCT01911325 · Novartis Pharmaceuticals
2013-10 – 2015-08 · Squamous Non-small Cell Lung Cancer
What this study did
NCT01634061 · Novartis Pharmaceuticals
2012-09 – 2015-07 · Castration-resistant Prostate Cancer
What this study did
NCT01576666 · Novartis Pharmaceuticals
2012-07 – 2015-04 · Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
What this study did
NCT02048787 · Novartis Pharmaceuticals
2014-03 – 2015-03 · Renal Impairment
What this study did
NCT02117817 · Rutgers, The State University of New Jersey
2015-02 – 2015-02-25 · Ovarian Cancer, Endometrial Cancer, Recurrent Ovarian Cancer, Recurrent Endometrial Cancer
What this study did
NCT01155453 · Novartis Pharmaceuticals
2010-04 – 2014-11 · Advanced and Selected Solid Tumors
What this study did
NCT01285466 · Novartis Pharmaceuticals
2011-01 – 2014-10 · Metastatic or Locally Advanced Solid Tumors
What this study did
NCT01820325 · Novartis Pharmaceuticals
2013-09-09 – 2014-06-18 · Non-Small Cell Lunch Cancer
What this study did
NCT01626209 · Novartis Pharmaceuticals
2012-07 – 2014-04 · Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology
What this study did
NCT01513356 · Sofia Perea, Director Clinical Trials Unit.
2012-10 – 2014-02 · Breast Cancer
What this study did
NCT01727128 · Novartis Pharmaceuticals
2011-10 – 2013-08 · Hepatic Impairment
What this study did
NCT01068483 · Novartis Pharmaceuticals
2008-11 – 2012-08 · Breast Cancer, Colon Cancer, Ovarian Cancer, Endometrium Cancer
What this study did
NCT01283503 · Novartis Pharmaceuticals
2009-10 – 2011-10 · Advanced Solid Tumor
What this study did

Competitive landscape

This drug's own stage for Head and Neck Squamous Cell Carcinoma: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Buparlisib: this drugDiscontinuedSmall moleculePI3K inhibitor (pan-class I)not yet gradedNo reviewed efficacy summary in this indication
CetuximabApprovedMonoclonal antibodyEGFRPartial signal
NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048).
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
NBTXR3Phase 3NanoparticleHafnium-oxide nanoparticle radioenhancernot yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OrdastobartPhase 2/3Monoclonal antibodyOX40 (agonist)not yet gradedNo reviewed efficacy summary in this indication
IzalontamabPhase 2Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Ozuriftamab VedotinPhase 2Antibody–drug conjugateROR2Partial signalNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
PepinemabPhase 1/2Monoclonal antibodySEMA4Dnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 June 2025Topline resultPhase 3 BURAN (NCT04338399) of buparlisib plus paclitaxel did not meet its primary endpoint of overall survival
Adlai Nortye · Source ↗